Introduction {#sec1-1}
============

Mandibular condylar cartilage is embryologically classified as secondary cartilage.^[@ref1]^ Secondary cartilage is somewhat different from primary cartilage; for example, it differs in origin, time of its appearance, and pattern of expression for several matrix components and growth factors.^[@ref1]^ Previously, we reported that mouse condylar cartilage derives from alkaline phosphatase (ALP)-positive progenitor cells of the periosteum that is continuous with the ossifying mandible that forms before the condylar cartilage.^[@ref7]^ Meanwhile, extracellular matrix (ECM) components are involved in organogenesis of bone or cartilage, and often utilized as marker molecules for each organ.^[@ref3]^ From this point of view, we investigated expression patterns of bone/cartilage matrix components, including collagen types I, II, X, aggrecan, bone sialoprotein (BSP), and osteopontin (OPN) (secreted phosphoprotein-1:Spp-1).^[@ref7]^ These previous studies confirm that expression patterns of matrix components in developing condylar cartilage differ from those in limb bud cartilage (representative primary cartilage), and they demonstrate that progenitor cells of condylar cartilage rapidly differentiate into hypertrophic chondrocytes. In the present *in situ* hybridization study, we focused on three other bone/cartilage matrix components, which involved cartilage formation and mineralization, to further elucidate structural features of developing condylar cartilage and limb bud cartilage.

Perlecan is a large heparan sulfate proteoglycan that is present in basement membranes and other extracellular matrices.^[@ref10]^ It has a wide variety of functions in normal development and disease processes; these roles include binding to other extracellular proteins, growth factors, and cell membrane receptors.^[@ref14]^ Additionally, *perlecan*-deficient mice display severe chondrodysplasia, which includes disorganized collagen fibrils and poor glycosaminoglycans, and this phenotype revealed that perlecan is essential for normal cartilage formation.^[@ref15],[@ref16]^ However, transition of *perlecan* mRNA expression in the mesenchymal cell condensation to the initial formation of cartilage in normal mice has not been reported for either secondary cartilage or primary cartilage. Thus, investigation of *perlecan* mRNA expression would clarify further structural features of both types of cartilage.

DMP1 (dentin matrix protein 1) was first identified as a product of a rat pulp incisor cDNA library; it belongs to SIBLING (small integrin-binding ligand, N-linked glycoprotein) protein family, and previously it was thought to be dentin-specific.^[@ref17]^ Subsequently, high levels of *DMP1* mRNA were detected in osteocytes and lower levels were seen in other mineralized or unmineralized tissues such as dental pulp, brain, and submandibular glands.^[@ref18]^ Regarding cartilage, *DMP1* mRNA is expressed in hypertrophic chondrocytes in fetal limb bud cartilage at E16.0, and this expression in hypertrophic chondrocytes persisted throughout later embryonic and postnatal development, indicating involvement of this molecule in cartilage mineralization.^[@ref23]^ Based on immunohistochemistry, DMP1 protein localization is complicated; for example, full-length DMP1 (108 kDa) and two proteolytic fragments (a 37-kDa N-terminal fragment and a 57-kDa C-terminal fragment) have different localization patterns in two different types of cartilage: limb bud cartilage^[@ref24]^ and postnatal rat mandibular condylar cartilage.^[@ref25]^ Thus, investigation of *DMP1* mRNA expression during the initial stages of cartilage formation would clarify features of both types of cartilage in terms of mineralization.

MEPE (matrix extracellular phosphoglycoprotein), like DMP1, is a member of the SIBLING family and a bone marker protein expressed in osteocytes.^[@ref26],[@ref27]^ *MEPE* is also expressed in odontoblasts, regenerating tissues after a fracture, and tumor tissue.^[@ref28],[@ref29]^ Stain *et al*.^[@ref30]^ recently reported that *MEPE* mRNA is expressed in hypertrophic chondrocytes in the growth plate of 3-week-old mice. However, expression of *MEPE* mRNA during the initial stages of cartilage formation was not investigated in any type of cartilage. Thus, the main purpose of this *in situ* hybridization study was to examine the expression of *perlecan, DMP1*, and *MEPE* mRNA in the developing mandibular condylar cartilage and the developing limb bud cartilage. In addition, we previously reported that MEPE immunoreactivity was clearly evident throughout the matrix of Meckel's cartilage in mice, rats, and humans; ^[@ref31]^ consequently, we hypothesized that MEPE may be a useful marker molecule for cartilage. Thus another purpose of this study is to further test this hypothesis by means of *in situ* hybridization, immunohistochemistry, and western immunoblot analysis.

Materials and Methods {#sec1-2}
=====================

Animals {#sec2-1}
-------

A total of 10 pregnant ICR mice, E12.0-18.0 (8 a.m. on the day of the vaginal plug was designated as E0), and five male 3-weeks-old mice were used for this study. Each animal was housed in facilities approved by Tokyo Medical and Dental University. Our animal-use protocol and experimental system were approved by the Institutional Animal Care and Use Committee of Tokyo Medical and Dental University (No. 0150011A).

RT-PCR {#sec2-2}
------

Mandibular condylar anlage or formed condylar cartilage was meticulously microdissected from embryonic mice at specific points within the E14.0-E16.0 window. ISOGEN (Nippon Gene, Tokyo, Japan) was used to extract total RNA from condylar cartilage of E15.0 and E16.0 and condylar anlage from E14.0. Primer Script RT reagent Kit and gDNA Eraser (Takara Bio Inc., Shiga, Japan) were used for RT-PCR to synthesize cDNA. SybrGreen Premix EX Taq II (Takara Bio Inc, Shiga, Japan) and a Light Cycler 480 Real-Time PCR System (Roche Diagnostics, Tokyo, Japan) were used for all real-time PCR amplification. Each primer sequence is listed in [Table 1](#table001){ref-type="table"}. The PCR conditions were as follows: initial denaturing at 95°C for 30 s followed by 40 cycles of denaturing at 95°C for 5 s, annealing at 60°C for 30 s, extension at 72°C for 30 s, and a final extension at 72°C for 7.5 min. β*-actin* mRNA levels were quantified as internal controls. Relative expression levels were calculated using the Δ(ΔCt) method. All data are expressed as the mean ± SD. The data analyses were performed with one-way analysis of variance for several group comparisons, and significance was determined using Tukey's comparison test. A P-value of \<0.01 was considered statistically significant. We examined three different samples for each embryonic day.

Tissue preparation {#sec2-3}
------------------

At each time point, pregnant mice were killed by cervical dislocation under ether anesthesia, after which each fetal mouse was killed by cervical dislocation. The heads and lower limbs were removed and then immersed in 4% paraformaldehyde (0.1 M phosphate buffer, pH 7.4) for 1 day at 4°C. Paraffin embedded serial sections (5 µm) were cut in the coronal plane (perpendicular to the sagittal plane) and parallel to the long axis of the condylar process of the mandible or longitudinally to the tibia. Sections were stained with 0.1% toluidine blue (0.1 M phosphate buffer, pH 7.4) for histological observations.

*In situ* hybridization {#sec2-4}
-----------------------

For *in situ* hybridization of *perlecan*, *DMP1*, and *MEPE*, total RNA was extracted from limb cartilage and bone; cDNA encoding mouse *perlecan* (NM_008305.3), *DMP1* (NM_016779.2), and *MEPE* (NM_053172.2), were then synthesized via RT-PCR. Each primer sequence is listed in [Table 2](#table002){ref-type="table"}. A representative PCR product for each gene was subcloned into a pCRII vector (Strategene, La Jolla, CA, USA); antisense and sense RNA probes were then synthesized for each gene. The Riboprobe *in vitro* Transcription System (Promega, Madison, WI) was used to label each probe with ^[@ref35]^S-UTP. *In situ* hybridization with ^[@ref35]^S-UTP labeled probes was performed as previously described.^[@ref32]^ Sections were dipped in emulsion (NTB, Kodak, Rochester, NY, USA) after hybridization and RNAase treatment, and then exposed for 2 weeks at 4°C for autoradiography. We extended exposure period up to 4wk to confirm enhanced signals would appear, but they were not recognized. Sense probes were used for negative control samples. We examined three different samples for each embryonic day, and the same results were obtained each time.

Immunohistochemistry {#sec2-5}
--------------------

A rat monoclonal antibody against perlecan (diluted 1:200 with PBS) was purchased from Seikagaku Corp (Tokyo, Japan). Rabbit polyclonal antibody against MEPE, LF-155 (diluted 1:200), was kindly supplied by Dr. Larry W. Fisher (Matrix Biology Unit, Craniofacial and Skeletal Disease Branch, NIDCR, NIH, Bethesda, MD, USA). LF-155 reacts only against COOH-terminal fragments of MEPE.^[@ref35],[@ref36]^ For detection of DMP1, mouse monoclonal antibody raised against rat DMP1 57-kDa fragments was used (diluted 1:500). This monoclonal antibody specifically recognizes C-terminal fragments of DMP1.^[@ref37]^ These antibodies were well characterized and used in our previous immunohistochemical studies.^[@ref31],[@ref37],[@ref38]^

Before antibody addition, the sections were immersed in PBS and digested with testicular hyaluronidase (25 mg/mL in phosphate buffered saline; Sigma Chemical Co., St. Louis, MO, USA) to remove masking with hyaluronan and chondroitin sulphate chains for 3 h at 37°C. Sections for DMP1 immunohistochemistry were then immersed in mouse IgG blocking reagent from a MOM kit (Vector Laboratories, Burlingame, CA, USA) to block endogenous mouse IgG activity. The streptavidin-biotin method with a Histofine SAB kit (Nichirei, Tokyo, Japan) was then performed as previously described.^[@ref7],[@ref31],[@ref38],[@ref39]^ The sections were treated with diaminobenzidine to visualize protein localization. Negative control sections were incubated with normal rabbit or mouse or rat IgG instead of the primary antibodies. Sections were observed after counter-staining with hematoxylin.

Protein extraction from bone and cartilage {#sec2-6}
------------------------------------------

Under anesthesia with diethyl ether and intraperitoneal injection of pentobarbital sodium (30 mg/kg body weight) (Kyoritu, Tokyo, Japan), bone of limbs, ribs, vertebra, and calvaria were dissected from 3-weeks-old mice and homogenized. The samples (2.8 g wet wt) were stirred for 72 h at 4°C in 30 mL of an E-extraction buffer (4 M guanidine HCl, 50 mM sodium acetate, 0.5 M Tetrasodium EDTA, pH 7.4) that contained a protease-inhibitor cocktail (Sigma-Aldrich).^[@ref40]^ After centrifugation, the supernatant was removed and the remaining residues were stirred in the same buffer for another 72 h. The solution was again centrifuged, the supernatant removed and mixed with the first extract. The solution was dialyzed with 0.5 M Sodium Acetate (pH 7.4) containing protease inhibitors for 24 h at 4°C. Precipitated insoluble proteins (presumably collagen) were removed by centrifugation, and the supernatant was again dialyzed with dH~2~O for another 48 h and freeze-dried (bone-derived samples). Meanwhile, to collect large amounts of pure cartilage without bone, tracheal cartilage (6 mg wet wt) was dissected and stirred in 6 mL of an G-extraction buffer (4 M guanidine HCl, 50 mM sodium acetate, pH 7.4) containing protease inhibitors cocktail.^[@ref40]^ The following steps were performed as described for bone-derived samples. Other tracheal cartilage specimens were fixed and embedded in paraffin, then subjected to immunohistochemistry to confirm whether postnatal tracheal cartilage also shows MEPE immunoreactivity.

Electrophoresis and Western immunoblotting {#sec2-7}
------------------------------------------

Samples of bone- or cartilage-derived protein (\~100 ng) were subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) in12.5% (W/V) gel. SDS-PAGE was done under reducing conditions, and protein bands were transferred to Immobilon-P membranes with Horizblot from ATTO (Tokyo, Japan). The membranes were then immersed in a solution of 3% bovine serum albumin in PBS for 1 h at RT to block any non-specific reactions. They were then reacted with mouse monoclonal antibody that was against a 57-kDa fragment of rat DMP1 (diluted 1:2000 with PBS) or rabbit polyclonal antibody against MEPE, LF-155 (diluted 1:1000), in PBS at 4°C overnight. The membranes were then incubated in biotin-labeled anti-mouse IgG+IgA+IgM (diluted 1:10 with PBS) or biotin-labeled anti-rabbit IgG (diluted 1:10) from HISTOFINE SAB kits for 1 h at 37°C, and subsequently incubated in peroxidase-labelled streptoavidin (diluted 1:10 with PBS) for 30 min at RT. Membranes were then washed in PBS and next treated with AEC (Nichirei) to detect any immunoreactivity. The membranes generated to detect MEPE were treated with ECL detection system (GE Healthcare UK Ltd., Little Chalfont, UK) and exposed to soft X-ray film.

Results {#sec1-3}
=======

RT-PCR analysis of perlecan, DMP1, and MEPE mRNA in developing mandibular condylar cartilage {#sec2-8}
--------------------------------------------------------------------------------------------

Based on RT-PCR analysis, *aggrecan* mRNA was barely evident in the condylar anlagen at E14.0. *Aggrecan* mRNA expression levels had increased modestly by E15.0 and were markedly upregulated by E16.0 ([Figure 1a](#fig001){ref-type="fig"}). *Perlecan* mRNA expression on E14.0 was similar to that on E15.0, but levels increased 2-fold by E16.0 ([Figure 1b](#fig001){ref-type="fig"}). In contrast, neither *DMP1* nor *MEPE* mRNAs was evident from E14.0 to E16.0 ([Figure 1 c,d](#fig001){ref-type="fig"}).

*In situ* hybridization in developing mandibular condylar cartilage {#sec2-9}
-------------------------------------------------------------------

Mandibular bone that contained many osteocytes was evident on E18.0 ([Figure 2a](#fig002){ref-type="fig"}). *DMP1* mRNA was expressed in many of these osteocytes ([Figure 2b](#fig002){ref-type="fig"}); in contrast, *MEPE* mRNA was expressed in fewer of these mandibular bone osteocytes ([Figure 2c](#fig002){ref-type="fig"}). These expression patterns were similar to patterns seen in previous studies,^[@ref18],[@ref26]^ indicating probes for *DMP1* and *MEPE* could be reliably used for this *in situ* hybridization study. At E14.0, the anlage of the future mandibular condylar process (designated the condylar anlage) was recognizable in the posterior position of the ossifying mandible, which comprised osteoid-like tissue. The condylar anlage consisted of a mesenchymal cell condensation, as previously described.^[@ref6],[@ref33]^ Cartilage formation indicated by matrix metachromasia was not observed in the anlage ([Figure 3a](#fig003){ref-type="fig"}). *Perlecan* mRNA was not detected in the anlage at this stage ([Figure 3b](#fig003){ref-type="fig"}). *DMP1* mRNA was slightly expressed in cells in the osteoid-like tissue, but not in the condylar anlage ([Figure 3c](#fig003){ref-type="fig"}). *MEPE* mRNA expression was not detected in the condylar anlage or in the osteoid-like tissue ([Figure 3d](#fig003){ref-type="fig"}). At E15.0, a metachromatically stained matrix, which indicated that the condylar cartilage had formed, was first detected in posterior to the ossifying mandible ([Figure 3e](#fig003){ref-type="fig"}). Several chondrocytes in this newly formed cartilage showed marked hypertrophy. The bone collar had formed around the cartilage ([Figure 3e](#fig003){ref-type="fig"}). *Perlecan* mRNA expression was detected in newly formed chondrocytes ([Figure 3f](#fig003){ref-type="fig"}). *DMP1* mRNA was expressed in the osteogenic cells of the bone collar and of the mandibular bone as well as in a few chondrocytes ([Figure 3g](#fig003){ref-type="fig"}). *MEPE* mRNA expression was barely detected both in the cartilage and the mandibular bone ([Figure 3h](#fig003){ref-type="fig"}). At E16.0, the condylar cartilage had increased in length, especially the hypertrophic cell zone; each zone had become clearly identifiable and distinct. In this study, condylar cartilages were classified according to the system developed by Luder *et al*.:^[@ref41]^ fibrous cell (articular cell) zone, polymorphic cell zone, flattened cell zone, and hypertrophic cell zone ([Figure 3i](#fig003){ref-type="fig"}). *Perlecan* mRNA was expressed in chondrocytes from flattened cell zone to upper hypertrophic cell zone, but *perlecan* mRNA expression was reduced in the lower hypertrophic cell zone ([Figure 3j](#fig003){ref-type="fig"}). At E16.0, *DMP1* mRNA was expressed in osteogenic cells of the bone collar, but not in chondrocytes ([Figure 3k](#fig003){ref-type="fig"}). *MEPE* mRNA expression was detected in a few osteocytes in mandibular bone, as described in [Figure 2b](#fig002){ref-type="fig"} (*data not shown*), but not in the bone collar or in the cartilage ([Figure 3l](#fig003){ref-type="fig"}).

### *In situ* hybridization in developing tibia {#sec3-1}

At E12.0, the anlage of the future tibia consisted of a mesenchymal cell condensation ([Figure 4a](#fig004){ref-type="fig"}). At this stage, *in situ* hybridization for *perlecan*, *DMP1*, and *MEPE* failed to show any positive reaction in this condensation ([Figure 4 b-d](#fig004){ref-type="fig"}). At E13.0, the anlage of the future tibia exhibited metachromasia by toluidine blue staining, indicating initial cartilage formation; this cartilage was designated tibial cartilage ([Figure 4e](#fig004){ref-type="fig"}); *Perlecan* mRNA was expressed in chondrocytes throughout this cartilage ([Figure 4f](#fig004){ref-type="fig"}), but *DMP1* and *MEPE* mRNA was not detected in tibial cartilage at this stage ([Figure 4](#fig004){ref-type="fig"} g,h). At E14.0, chondrocyte hypertrophy was first observed in the diaphysis of the tibial cartilage. At this stage, the hypertrophic cell zone could be divided into two zones: the upper hypertrophic cell zone, which contained relatively large hypertrophic cells, and the lower hypertrophic cell zone, which was located in the center of diaphysis and contained relatively small hypertrophic chondrocytes ([Figure 4i](#fig004){ref-type="fig"}). *Perlecan* mRNA was strongly expressed in chondrocytes throughout the entire proliferation and maturation zone, but expression was weaker in the hypertrophic cell zone ([Figure 4j](#fig004){ref-type="fig"}). *DMP1* mRNA was expressed in osteogenic cells of the bone collar and in many hypertrophic chondrocytes of the lower hypertrophic cell zone ([Figure 4k](#fig004){ref-type="fig"}). *MEPE* mRNA expression was not detected at this stage ([Figure 4l](#fig004){ref-type="fig"}). Negative controls using sense probes showed no positive reactions at any stage examined (*data not shown*). Expression patterns of mRNA for three molecules were summarized in [Figure 5](#fig005){ref-type="fig"}.

Immunohistochemistry in developing mandibular condylar cartilage and tibial cartilage {#sec2-10}
-------------------------------------------------------------------------------------

In developing condylar cartilage at E14.0, perlecan immunoreactivity was evident in Meckel's cartilage, but not in the anlage ([Figure 6a](#fig006){ref-type="fig"}). *DMP1* immunoreactivity was weak but definite in the osteoid-like tissue, but it was not evident in the condylar anlage or Meckel's cartilage ([Figure 6b](#fig006){ref-type="fig"}). MEPE immunoreactivity was not detected in the condylar anlage, but it was evident in the osteoid-like tissue and in Meckel's cartilage ([Figure 6c](#fig006){ref-type="fig"}). At E15.0, perlecan immunoreactivity was clearly detected in newly formed cartilage matrix ([Figure 6d](#fig006){ref-type="fig"}); DMP1 immunoreactivity was evident in the bone collar, but not in the cartilage matrix ([Figure 6e](#fig006){ref-type="fig"}); MEPE immunoreactivity was evident in the bone collar and in the cartilage matrix ([Figure 6f](#fig006){ref-type="fig"}). At E16.0, perlecan immunoreactivity was detected throughout the cartilage matrix ([Figure 6g](#fig006){ref-type="fig"}); DMP1 immunoreactivity was detected in the bone collar, but not in the cartilage matrix ([Figure 6h](#fig006){ref-type="fig"}); MEPE immunoreactivity was detected in the bone collar and throughout the cartilage matrix ([Figure 6i](#fig006){ref-type="fig"}). In developing limb bud cartilage at E12.0, immunohistochemistry for perlecan, DMP1, and MEPE failed to show any positive reaction in the in the tibial anlage ([Figure 6 j-l](#fig006){ref-type="fig"}). At E13.0, perlecan and MEPE immunoreactivity was evident throughout the cartilage matrix ([Figure 6](#fig006){ref-type="fig"} m,o); DMP1 immunoreactivity was not detected at this stage ([Figure 6n](#fig006){ref-type="fig"}). At E14.0, perlecan immunoreactitivity was detected throughout the cartilage matrix ([Figure 6p](#fig006){ref-type="fig"}); DMP1 immunoreactivity was detected in the bone collar and in the lower hypertrophic cell zone ([Figure 6q](#fig006){ref-type="fig"}); MEPE immunoreactivity was detected in the bone collar and throughout the cartilage matrix ([Figure 6r](#fig006){ref-type="fig"}). In maxillary region at E16.0, MEPE immunoreactivity was detected in some bone lacunae, but not in the oral epithelium in the same section ([Figure 6 s,t](#fig006){ref-type="fig"}), supporting the specificity of the antibody used in the present study.

Western immunoblotting for DMP1 and MEPE in bone- or cartilage-derived samples {#sec2-11}
------------------------------------------------------------------------------

Tracheal cartilage from 3-week-old animals exhibited metachromasia throughout the cartilage ([Figure 7a](#fig007){ref-type="fig"}). DMP1 immunoreactivity was not detected in the cartilage matrix ([Figure 7b](#fig007){ref-type="fig"}), but MEPE immunoreactivity was clearly recognized in the cartilage matrix, as seen in fetal cartilages ([Figure 7c](#fig007){ref-type="fig"}).

Western immunoblotting indicated that DMP1 antibody clearly recognized a strong protein band of 65 kDa in bone-derived samples, but a weaker band in cartilage-derived samples ([Figure 7d](#fig007){ref-type="fig"}). MEPE antibody recognized a protein band of 62 kDa in bone-derived samples and two bands, one of 67 kDa and another of 59 kDa, in cartilage-derived samples ([Figure 7e](#fig007){ref-type="fig"}).

Discussion {#sec1-4}
==========

Perlecan {#sec2-12}
--------

In the present study, we first reported transition of *perlecan* mRNA expression from mesenchymal cell condensation to initial cartilage formation in normal limb bud cartilage using *in situ* hybridization. *Perlecan* mRNA expression was not detected in mesenchymal cell condensations at E12.0; it was first detected in the newly formed cartilage at E13.0. At E14.0, *perlecan* mRNA expression was weak in hypertrophic chondrocytes of the diaphysis. Meanwhile, perlecan immunoreactivity was evident throughout the tibial cartilage; these findings indicated that cells developing into mature chondrocytes actively synthesized perlecan, but the hypertrophic chondrocytes had downregulated perlecan synthesis. This discordance between mRNA expression and protein accumulation was similar to the discordance noted for aggrecan localization in the tibial cartilage.^[@ref42]^

In the condylar cartilage, *perlecan* mRNA expression was not detected in the E14.0 anlage, which consisted of mesenchymal cell condensation: it was first detected in newly formed cartilage at E15.0. We have previously described that, as newly formed chondrocytes can simultaneously express collagen type I, II, X, and aggrecan, progenitor cells of condylar cartilage rapidly differentiate into hypertrophic chondrocytes; notably, this process is different from that in limb bud cartilage.^[@ref6],[@ref7],[@ref9]^ Our current results indicated that newly formed hypertrophic chondrocytes can also express *perlecan* mRNA, supporting our previous theory. At E16.0, *perlecan* mRNA expression was reduced in lower hypertrophic cell zone, although immunoreactivity was detected throughout the cartilage matrix. These results are consistent with results previously described for aggrecan expression,^[@ref9]^ and realtime PCR in the present study demonstrated that *perlecan* mRNA showed a similar expression pattern to *aggrecan* mRNA. Thus, these results indicated that perlecan expression is concomitant with aggrecan expression during the process of condylar cartilage formation. Thus, we believe that perlecan is a component of an essential cartilage matrix, as perlecan gene-knockout studies have indicated.^[@ref15]^

DMP1 {#sec2-13}
----

DMP1 is primarily expressed in mineralized tissues such as osteocytes and odontoblasts.^[@ref17],[@ref43]^ *DMP1*-deficient mice displayed severe deletion of bone and dentin mineralization and an abnormal growth plate, suggesting that DMP1 play a role in mineralization. Notably, Feng *et al*.^[@ref23]^ reported that *DMP1* mRNA was highly expressed in hypertrophic chondrocytes within the diaphysis of limb bud cartilage at E16.0 and in the growth plate of 8-weeks-old mice. Meanwhile, in limb bud cartilage, cartilage marker molecules further divide the hypertrophic cell zone into upper hypertrophic cell zone and lower hypertrophic cell zone, and the latter expresses OPN as well as type X collagen.^[@ref8],[@ref44]^ During initial formation of the hypertrophic cell zone in limb bud cartilage (before bone marrow cavity formation), both *OPN* and *BSP* mRNAs are expressed in the lower hypertrophic cell zone (mineralizing cartilage core), although the expression of *BSP* mRNA is weaker than that of *OPN.*^[@ref8],[@ref45]^ In the present study, hypertrophic cell zone in the tibial cartilage was first observed at E14.0, and *DMP1* mRNA expression was detected in lower hypertrophic cell zone; this pattern was similar to the pattern of *OPN* mRNA. Thus, *DMP1* is potentially another marker molecule for lower hypertrophic cell zone in limb bud cartilage.

In newly formed condylar cartilage at E15.0, *BSP* mRNA is more extensively expressed than *OPN* mRNA; this pattern differed from that in limb bud cartilage at the corresponding stage.^[@ref8]^ In the present study, *DMP1* mRNA was detected in a few chondrocytes in newly formed condylar cartilage at E15.0; this pattern was similar to that of *OPN*. *DMP1* mRNA expression was, however, hardly detected at E16.0. Thus *DMP1* expression in hypertrophic chondrocytes was only transient, and DMP1 may not have important roles in developing condylar cartilage, compared with OPN and BSP. Meanwhile, intense *DMP1* mRNA expression was observed both in newly formed bone collar around the diaphysis of tibial cartilage and around newly formed condylar cartilage, indicating DMP1 seems to be involved in the formation of bone collar in both types of cartilage.

*In vitro* findings suggest that the full-length DMP1 inhibits mineralization, but N-terminal and C-terminal fragments promote hydroxyapatite formation.^[@ref46],[@ref47]^ Maciejewska *et al*.^[@ref48],[@ref49]^ demonstrated that, in the growth plate of long bones in newborn rats, N-terminal DMP1 fragments were predominantly localized in the matrix of the proliferation and hypertrophic cell zone, while the C-terminal fragments were primarily localized in the hypertrophic cell zone and mineralization front, indicating the C-terminal fragments are involved in cartilage mineralization. Based on our western blot analysis, a protein band of 65 kDa reacted with anti-DMP1 antibody in bone-derived samples, confirming that this antibody can recognize C-terminal fragments of DMP1. Based on immunohistochemistry, C-terminal fragments were recognized in the newly formed lower hypertrophic cell zone in the tibial cartilage at E14.0; this pattern was identical to that of *DMP1* mRNA expression. These results were similar to previous finding for the postnatal rat growth plate,^[@ref48],[@ref49]^ and we reasoned that C-terminal fragments may also be involved in initial mineralization of limb bud cartilage.

Regarding the mandibular condylar cartilage, the C-terminal fragments were mainly localized in the nuclei of chondroblastic and hypertrophic layers and cartilage-bone interface in postnatal rat condylar cartilage.^[@ref25]^ In the present study, immunoreactivity from C-terminal fragments was barely evident in developing condylar cartilage; this finding was not consistent with previous findings^[@ref25]^ or with our findings for tibial cartilage. These differences were due to differences in the developmental stages and species examined, and they suggested that roles of C-terminal fragments in the developing condylar cartilage may not be as important as those in the limb bud cartilage. This is also supported by results of *in situ* hybridization described above.

MEPE {#sec2-14}
----

MEPE is predominantly expressed in osteocytes.^[@ref26],[@ref50],[@ref51]^ *In situ* hybridization in the present study confirmed this observation, indicating that the probes used were reliable markers for *in situ* hybridization of this molecule. *MEPE*-deficient mice display an increase in bone mass and enhancement of mineralization; conversely, *MEPE*-overexpressing mice had wider epiphyseal growth plates and expansion of primary cancellous bone.^[@ref50],[@ref52]^ Thus, MEPE may be involved in mineralization of cartilage matrix, as indicated by a report on *MEPE* mRNA expression in hypertrophic chondrocytes of the postnatal murine growth plate.^[@ref30]^ Nevertheless, the exact role of MEPE in cartilage remains unclear. Our previous study^[@ref31]^ shows that MEPE immunoreactivity is evident in Meckel's cartilage in fetal mice and rats and in condylar cartilage in human fetuses, and we hypothesized that MEPE may be useful as a marker molecule for cartilage.

To test this hypothesis, we performed *in situ* hybridization with a ^[@ref35]^S-UTP-labeled RNA probe for *MEPE*. No mRNA expression was detected in any chondrocytes in the tibial cartilage or the condylar cartilage, even when exposure period was extended up to 4 weeks; this finding was consistent with the results of our real-time PCR analysis. MEPE immunoreactivity was, however, detected throughout the cartilage matrix in Meckel's, tibial, condylar, and tracheal cartilages, as we previously described. As negative controls never showed positive reactions, we believed that this immunoreactivity was not background staining. To determine whether this positive reaction was a non-specific reaction, we performed western immunoblotting with bone- and tracheal cartilage-derived samples. Previous western immunoblotting studies demonstrated that a protein band of 55 kDa in rat bone^[@ref53]^ and 50 kDa in rat dental pulp^[@ref36]^ were recognized as full-length MEPE.

In the present study, a protein band of 62 kDa in bone-derived samples reacted with antibody, indicating that this antibody could recognize full-length MEPE. The slight increase in molecular weight may be due to differences between species or post-translational modification, such as phosphorylation or glycosylation. In cartilage-derived samples, two bands of 67 kDa and 59 kDa were detected. Wang *et al*.^[@ref36]^ identified three forms of MEPE protein, 50, 38, and 25 kDa in rat pulp tissue; these finding indicate that the low-molecular weight proteins are cleaved forms of MEPE. We cannot confirm whether these bands were products of post-translational modification or cleaved forms of MEPE, but believe that there are some proteins that the MEPE antibody can recognize and that the immunoreactivity in cartilage was not a non-specific reaction.

It is conceivable that MEPE protein accumulated gradually in the cartilage, even though the mRNA expression levels were consistently below the limits of detection of *in situ* hybridization. We cannot, however, confirm that MEPE is a useful marker molecule for cartilage, and we will modify our previous hypothesis. In addition, the exact role of MEPE in developing condylar/tibial cartilage still remains unclear, since MEPE immunoreactivity was evenly recognized throughout cartilage matrix.
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![Real-time RT-PCR analysis of *perlecan*, *DMP1*, and *MEPE* mRNA in condylar cartilage. a) *Aggrecan* mRNA was barely evident in the condylar anlagen at E14.0; *aggrecan* mRNA expression levels had increased modestly by E15.0 and were markedly upregulated by E 16.0. b) *Perlecan* mRNA expression on E14.0 was similar to that on E15.0, but levels increased 2-fold by E16.0. c, d) Neither *DMP1* nor *MEPE* mRNAs was evident from E14.0 to E16.0. Data are presented as means ± SD (n=3).](ejh-2015-3-2553-g001){#fig001}

![A higher magnification of mandibular bone at E18.0. Toluidine blue staining (a) and *in situ* hybridization for *DMP1* (b) and *MEPE* (c). Mandibular bone contained many osteocytes (arrowheads in a). *DMP1* mRNA was expressed in many of these osteocytes (arrowhead in b), but *MEPE* mRNA was expressed in fewer of them (arrowheads in c). Scale bars: 100 µm.](ejh-2015-3-2553-g002){#fig002}

![Condylar anlage/cartilage in coronal plane at E14.0 (a-d), E15.0 (e-h), and E16.0 (i-l). Toluidine blue staining (a,e,i), and *in situ* hybridization for *perlecan* (b,f,j), *DMP1* (c,g,k), and *MEPE* (d,h,l). Inset in (g) shows a bright field image of identical section stained with toluidine blue. a) Although the ossifying mandible was recognizable (arrowhead), metachromasia was not observed in the condylar anlage (arrow). b-d) *Perlecan, DMP1*, and *MEPE* mRNA expression were not detected in the anlage (arrows in b-d), but *DMP1* mRNA was slightly expressed in cells in the osteoid-like tissue (arrowheads in c). e) A metachromatically stained matrix was first detected in the anlage (arrow); note that newly formed chondrocytes showed a considerable hypertrophy, and the bone collar had formed around the cartilage (arrowhead). f) *Perlecan* mRNA expression was detected in newly formed chondrocytes (arrows). g) *DMP1* mRNA was expressed in the osteogenic cells of the bone collar (arrowheads) as well as in a few chondrocytes (arrows). h) *MEPE mRNA* expression was barely detected both in the cartilage (arrow) and the bone collar (arrowhead). i) Cell zones in the condylar cartilage had become distinct: fibrous cell (articular cell) zone (F), polymorphic cell zone (P), flattened cell zone (Fl), and hypertrophic cell zone (H). j) *Perlecan* mRNA was expressed in chondrocytes from flattened cell zone to upper hypertrophic cell zone (arrows), but reduced in the lower hypertrophic cell zone (\*). k) *DMP1* mRNA was expressed in osteogenic cells of the bone collar (arrowheads), but not in chondrocytes (arrows). l) *MEPE* mRNA expression was not detected in the bone collar (arrowheads) or in the cartilage (arrow). Scale bars: 100 µm.](ejh-2015-3-2553-g003){#fig003}

![The anlage of the future tibia at E12.0 (a-d), and tibial cartilage at E13.0 (e-h), E14.0 (i-l). Toluidine blue staining (a,e,i) and *in situ* hybridization for *perlecan* (b,f,j), *DMP1* (c,g,k), and *MEPE* (d,h,l). a) The anlage of the future tibia consisted of a mesenchymal cell condensation (arrow). b-d) *Perlecan*, *DMP1*, and *MEPE* mRNA were not expressed in the condensation (arrows). e) A metachromatically stained matrix was first detected in the anlage of the future tibia (arrow). f) *Perlecan* mRNA was expressed in chondrocytes throughout the cartilage (arrow). g,h) *DMP1* and *MEPE* mRNA were not detected in tibial cartilage (arrows). i) Proliferative (P), maturation (M), and hypertrophic cell zone (H) had become clearly identifiable in the cartilage, and hypertrophic cell zone could be divided into two zones: the upper hypertrophic cell zone (U) and the lower hypertrophic cell zone (L). j) *Perlecan* mRNA was expressed in chondrocytes throughout the entire proliferative and maturation cell zone (arrows), but expression was weaker in the hypertrophic cell zone (\*). k) *DMP1* mRNA was expressed in the osteogenic cells of the bone collar (arrowheads) and in chondrocytes of the lower hypertrophic cell zone (arrows). l) *MEPE* mRNA expression was not detected both in the bone collar (arrowhead) or in the cartilage (\*). Scale bars: 100 µm.](ejh-2015-3-2553-g004){#fig004}

![Schematic representations of the expression pattern of *perlecan*, *DMP1*, and *MEPE* based on the present findings. a) Condylar anlage/cartilage at E14.0 to E16.0. b) Tibial cartilage at E13.0 and E14.0.](ejh-2015-3-2553-g005){#fig005}

![Condylar anlage/cartilage at E14.0 (a-c), E15.0 (d-f), E16.0 (g-i), and maxillary region at E16.0 (s,t); t) is the higher magnification of rectangular area of (s). The anlage of future tibia at E12.0 (j-l), and tibial cartilage at E13.0 (m-o), and E14.0 (p-r). Immunohistochemistry for perlecan (a,d,g,j,m,p), DMP1 (b,e,h,k,n,q), and MEPE (c,f,i,l,o,r,s,t). a) Perlecan immunoreactivity was evident in Meckel's cartilage (M), but not in the anlage (arrow). b) DMP1 immunoreactivity was weak but definite in the osteoid-like tissue (arrowhead), but not in the condylar anlage (arrow) or Meckel's cartilage (M). c) MEPE immunoreactivity was not detected in the condylar anlage (arrow), but it was evident in the osteoid-like tissue (arrowhead) and in Meckel's cartilage (M). d) Perlecan immunoreactivity was clearly detected in newly formed cartilage matrix (arrow). e) DMP1 immunoreactivity was evident in the bone collar (arrowhead), but not in the cartilage matrix (arrow). f) MEPE immunoreactivity was evident in the bone collar (arrowhead) and in the cartilage matrix (arrow). g-i) Immunostaining patterns were similar to those of E15.0. j-l) Perlecan, DMP1, and MEPE immunoreactivity were not detected in the mesenchymal cell condensation (arrows). m-o) Perlecan and MEPE immunoreactivity was evident in the matrix throughout the cartilage matrix (arrows in m and o), but DMP1 immunoreactivity was not detected (arrow in n). p) Perlecan immunoreactitivity was detected throughout the cartilage matrix (arrows). q) DMP1 immunoreactivity was detected in the bone collar (arrowheads) and in the lower hypertrophic cell zone (\*). r-t) MEPE immunoreactivity was detected in the bone collar (arrowheads in r), throughout the cartilage (arrows in r), and in some bone lacunae (arrowheads in t), but not in the oral epithelium (asterisk in t). Scale bars; a-r) 100 µm; s,t) 80 µm.](ejh-2015-3-2553-g006){#fig006}

![Tracheal cartilage at 3 weeks old (a-c) and Western immunoblotting for DMP1 and MEPE in bone- or cartilage- derived samples (d,e). a) Tracheal cartilage matrix exhibited metachromasia by toluidine blue staining (arrows). (b) DMP1 immunoreactivity was not detected in the cartilage matrix (arrows). c) MEPE immunoreactivity was clearly recognized in the cartilage matrix (arrows). d) DMP1 antibody clearly recognized a strong protein band of 65 kDa in bone-derived samples (arrow), but a weaker band in cartilage-derived samples (arrowhead). e) MEPE antibody recognized a protein band of 62 kDa in bone-derived samples (arrowhead) and two bands, one of 67 kDa (black arrow) and another of 59 kDa (white arrow) in cartilage-derived samples. Scale bars: 50 µm.](ejh-2015-3-2553-g007){#fig007}

###### 

Primer sets for real-time RT-PCR.

  -----------------------------------------------------------
  cDNA         Primer sequence (5\'→3\')             Size
  ------------ ------------------------------------- --------
  *Perlecan*   Forward: AGCCGCAGCAAGGACTTCA\         174 bp
               Reverse: CGTCTACTTGGATGGAGCCTCT       

  *DMP1*       Forward: AGCTGGGCTACATTGCTTTGG\       155 bp
               Reverse: TCCAGGCTTTGCTACTGTGGAAC      

  *MEPE*       Forward: GAGTCGTCATCCAGTGGGAGTTC\     171 bp
               Reverse: AGGTCTGTTGGCTTGCTCAGTTC      

  *Aggrecan*   Forward: AGTGGATCGGTCTGAATGACAGG\     105 bp
               Reverse: AGAAGTTGTCAGGCTGGTTTGGA      

  *β-actin*    Forward: CATCCGTAAAGACCTCTATGCCAAC\   171 bp
               Reverse: ATGGAGCCACCGATCCACA          
  -----------------------------------------------------------

DMP1, dentin matrix protein 1; MEPE, matrix extracellular phosphoglycoprotein.

###### 

Primer sets for RNA probes.

  --------------------------------------------------------
  cDNA         Primer sequence (5\'→3\')          Size
  ------------ ---------------------------------- --------
  *Perlecan*   Forward: CCGGGCTCTGGTAAATTTTA\     791 bp
               Reverse: CTGCCATCCCTGCAGTCTTC      

  *DMP1*       Forward: GTGCTCTCCCAGTTGCCAGATA\   373 bp
               Reverse: TGATGAGGACTCCACAGACAC     

  *MEPE*       Forward: CTCCAGCAAAGCTGAAGT\       611 bp
               Reverse: GACAGCAGCGAGTCGTCATC      
  --------------------------------------------------------
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